ReviewExploration (Beijing, China)2022
Stimuli-responsive crosslinked nanomedicine for cancer treatment.
Review in Exploration (Beijing, China), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Tumor-Selective Vascular Modulation by Acid-Cleavable Retro-Inverso Bradykinin Conjugates Enhances the Antitumor Efficacy of Nanomedicine.ACS omega · 2026Article
- Covalent "Locking" of Prodrug Nanoassemblies via Thiol-Ene Click Crosslinking for Potent Antitumor Therapy.Advanced healthcare materials · 2026Article
- Emerging Nanoreactors for Precision Disease Treatment: From Principles to Biomedical Applications.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Silencing SGO2 by Oxamic Acid Dissociates Glycolysis and BRCA1-Mediated DNA Repair to Improve the Chemosensitivity of Lung Adenocarcinoma.Exploration (Beijing, China) · 2026Article
- Bioactive manganese oxide nanoassembly as a highly sensitive magnetic resonance imaging probe for grading diagnosis of liver injury.Journal of nanobiotechnology · 2026Article
- Acquisition of KQuantitative imaging in medicine and surgery · 2026Article
- Nanomaterial-Enabled Modulation of Tumor-Associated Macrophages and Dendritic Cells to Enhance Cancer Immunotherapy.Nanomaterials (Basel, Switzerland) · 2026Review
- Exosome-Inspired Nanocarriers in Cancer Therapy: Bio-Derived Nanotechnology Meets Nano Drug Delivery.International journal of nanomedicine · 2026Review
- Multifunctional hydrogels for synergistic therapy of cutaneous melanoma-associated tumor recurrence and wound regeneration.Materials today. Bio · 2025Review
- A bufalin and CRISPR/Cas9 ribonucleoprotein-loaded calcium lactate nanomedicine for pyroptosis/apoptosis and synergistic cancer immunotherapy.Materials today. Bio · 2025Article
- Bio-Functional Nanomaterials for Enhanced Lung Cancer Therapy: The Synergistic Roles of Vitamins D and K.Journal of functional biomaterials · 2025Review
- Tumor suppressor protein-inspired peptide for siRNA delivery and synergistic cancer therapy.Fundamental research · 2025Article
- Recent Advances in Nanomedicine: Cutting-Edge Research on Nano-PROTAC Delivery Systems for Cancer Therapy.Pharmaceutics · 2025Review
- Tumor microenvironment-activated Zn//MnOScience advances · 2025Article
- Drug Delivery System Targeting Cancer-Associated Fibroblast for Improving Immunotherapy.International journal of nanomedicine · 2025Review
- Advances of Stimuli-Responsive Amphiphilic Copolymer Micelles in Tumor Therapy.International journal of nanomedicine · 2025Review
- Smart Cancer Nanomedicine for Synergetic Therapy.Current medicinal chemistry · 2025Review
- Basic helix-loop-helix ARNT like 1 regulates the function of immune cells and participates in the development of immune-related diseases.Burns & trauma · 2025Review
- Hydrophilic Ethylene Glycol Fragments: A Determinant Affecting the Therapeutic Index of Paclitaxel Prodrug Nanoassemblies.ACS central science · 2024Article
- Targeted Delivery of STING Agonist via Albumin Nanoreactor Boosts Immunotherapeutic Efficacy against Aggressive Cancers.Pharmaceutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomedicines are attractive paradigms to deliver drugs, contrast agents, immunomodulators, and gene editors for cancer therapy and diagnosis. However, the currently developed nanomedicine suffers from poor serum stability, premature drug release, and lack of responsiveness. Crosslinking strategy can be utilized to overcome these shortcomings by employing stimuli-responsive chemical bonds to tightly hold the nanostructure and releasing the payloads spatiotemporally in a highly controlled manner. In this Review, we summarize the recently ingenious design of the stimuli-responsive crosslinked nanomedicines (SCN) in the field of cancer treatment and their advances in circumventing the drawbacks of the conventional drug delivery system. We classify the SCNs into three categories based on the crosslinking strategies, including built-in, on-surface, and inter-particle crosslinking nanomedicines. Thanks to the stimuli-responsive crosslinkages, SCNs are capable of keeping robust stability during systemic circulation. They also respond to the particular tumoral conditions to experience a series of dynamic changes, such as the changes in size, surface charge, targeting moieties, integrity, and imaging signals. These characteristics allow them to efficiently overcome different biological barriers and substantially improve the drug delivery efficiency, tumor-targeting ability, and imaging sensitivities. With the examples discussed, we envision that our perspectives can inspire more attempts to engineer intelligent nanomedicine to achieve effective cancer therapy and diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.